Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
Prescription Benefits Consultant Sees Opportunities for Employers in Debate Over Rebates
May 13th 2019As pharmaceutical manufacturers and pharmacy benefit managers point fingers over who is responsible for high drug prices, employers have the opportunity to demand change to business as usual, consultant Chris Robbins of Arxcel says.
Chemo, Then Radiotherapy, May Boost Survival for Patients With Advanced Hodgkin Lymphoma
May 2nd 2019Radiotherapy after chemotherapy is controversial, as evidenced by the fact that doctors for some patients in the study did not follow the protocol for those assigned to radiotherapy and may have affected the results.
Few At-Risk Adults Are Being Referred to Diabetes Prevention Programs, Study Finds
April 27th 2019The CDC created the National Diabetes Prevention Program following a study of a lifestyle intervention; new results show that more than a third of adults who are referred to a program take part, but only a fraction are referred.
CGM Linked to Low A1C Among Blog Readers With Type 1 Diabetes
April 24th 2019The study by researchers at Penn State College of Medicine found those with type 1 diabetes who read blogs had lower glycated hemoglobin (A1C) levels, and the combination of reading blogs and using continuous glucose monitoring produced the best glycemic control.
Harvard Team Designs Algorithm for HRD, May Find More Patients Eligible for PARP Inhibitors
April 17th 2019The scientists used machine learning to test the algorithm and believe it could double the number of women who would be treated with poly (ADP-ribose) polymerase (PARP) inhibitors for breast cancer.
Providers, Industry Raise Concerns About CMS Plan for CAR T-Cell Reimbursement, Reporting on PROs
April 16th 2019Academic medical centers and a group representing community oncology practices have both raised concerns about CMS’ proposed reimbursement plan for chimeric antigen receptor (CAR) T-cell therapy, the individually manufactured gene treatments that are revolutionizing cancer care. The plan will be finalized next month, a year after the federal government launched a national coverage analysis to determine how to pay for these lifesaving yet expensive cancer treatments.
Experimental Cancer Vaccine Shrinks Tumors in Form of Non-Hodgkin Lymphoma
April 13th 2019A preliminary study discussed how a vaccine regimen stimulated dendritic cells to attack tumors, which could point to a new way of making immunotherapy effective in cancers that have proved resistant to treatment thus far.
Sanofi Offer Sets Monthly Price of $99 for Insulin Supply
April 10th 2019The program comes as Congress has singled out the cost of insulin in its scrutiny of drug prices. Patients with type 1 diabetes cannot survive without the hormone, and press reports have highlighted the plight of young adults who ration insulin after they reach age 26 and cannot stay on family insurance plans.
Step Therapy in Medicare Advantage Hurts Patients, Providers, Says Schwartzberg
April 6th 2019Step therapy, which requires that patients try the payer’s preferred treatment before the one a physician recommends, is harmful to both sides of the doctor-patient relationship, according to Lee B. Schwartzberg, MD, medical director of the West Cancer and Research Institute, who spoke at the 2019 Community Oncology Conference, held in Orlando, Florida.
Pharma Discusses How to Reframe Value in Era of Precision Medicine, Combinations
April 6th 2019Healthcare experts may agree the shift from volume to value is well under way, but the definition of value has many answers, according to pharmaceutical company representatives discussing the issue at the 2019 Community Oncology Conference in Orlando, Florida.